Antimicrobial resistance is an urgent global public health threat. Prevention tools, such as vaccines, are an effective tool to slow the emergence and spread of antimicrobial resistance and to save lives in the United States and around the world. Vaccines can help prevent infections from happening in the first place, thereby reducing use or misuse of antibiotics. Vaccines can also reduce infection duration or severity and reduce transmission of antimicrobial-resistant pathogens. That’s why CDC and partners are committed to driving innovation to develop and deploy vaccines to help slow the emergence and spread of antimicrobial resistance.
Join us to learn more about CDC’s antimicrobial resistance investments and how our partners are implementing this work.
Anthony (Tony) Fiore, MD, MPH, FIDSA
Anthony (Tony) Fiore, MD, MPH, is a medical epidemiologist and infectious diseases physician. Currently, he is an independent consultant with HilleVax, Inc., providing literature and data reviews relevant to a norovirus vaccine being evaluated in clinical trials. Recently he completed a contract with the World Health Organization, aiding in developing guidelines and metrics for measuring the impact of vaccines on antibiotic resistance.
Before working as an independent consultant, Dr. Fiore spent 26 years working at CDC, the last six years being spent as Chief of the Epidemiology, Research, and Innovations Branch in the Division of Healthcare Quality Promotion (DHQP) in CDC’s National Center of Emerging and Zoonotic Infectious Diseases. In this role, he collaborated on numerous projects aimed at preventing or reducing healthcare-associated infections and sepsis. He also worked on respiratory infections, viral hepatitis, and parasitic diseases.